ASX-listed healthcare companies are increasingly teaming up with universities to fast-track new therapies, combining academic ...
A self-acupressure app helped nearly 60% of women with ovarian cancer no longer experience cancer-related fatigue.The MeTime app, which teaches individuals how to perform self-acupressure, ...
Ovarian cancer (OC) is a "silent killer" with an annual incidence of 11.2 per 100,000 and mortality of 7.6 per 100,000. Most cases are diagnosed at ...
Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.
One of oncology’s biggest challenges is that the same treatment can work well for some patients but fail completely in others ...
MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2SK), engineered to precisely deliver clinically ...
One of oncology's biggest challenges is that the same treatment can work well for some patients but fail completely in others ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results